ARID1A and gastric cancer: For example, ARID1A is mutated in 46–57% of ovarian clear-cell carcinoma, 27% of gastric cancer, 17.5% of colon and rectal cancers, 16.7% of cholangiocarcinoma, 13% of hepatocellular carcinoma, 11% of colorectal adenocarcinoma, 9% of endometrial carcinoma, and 2.5% of malignant melanoma [19].